Microbial Cytotoxic Effect of 212Pb in Radiopharmaceuticals.

IF 2.4 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Aaron T Schatzmann, Tania A Stallons, Rachel Rivera, Quy P Nguyen, Rémy Dureau, Julien J Torgue
{"title":"Microbial Cytotoxic Effect of <sup>212</sup>Pb in Radiopharmaceuticals.","authors":"Aaron T Schatzmann, Tania A Stallons, Rachel Rivera, Quy P Nguyen, Rémy Dureau, Julien J Torgue","doi":"10.1089/cbr.2024.0208","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> The cytotoxic effect of <sup>212</sup>Pb on microbial growth was examined, using six microorganisms, at clinically relevant time points, to determine the potency of <sup>212</sup>Pb as a self-sterilizing agent in radiopharmaceuticals using [<sup>212</sup>Pb]Pb-DOTAMTATE. <b><i>Materials and Methods:</i></b> Vials of radiolabeled [<sup>212</sup>Pb]Pb-DOTAMTATE, nonradiolabeled DOTAMTATE, and appropriate media were inoculated with <i>Bacillus spizizenii</i>, <i>Candida albicans, Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus,</i> or <i>Aspergillus brasiliensis</i>. Samples from each vial type were plated onto tryptic soy agar or Sabouraud dextrose plates and allowed to grow at optimal temperature for each strain to obtain quantifiable colony forming units (CFU). <b><i>Results:</i></b> Each microbial organism observed at least a 6 log reduction in total CFUs after 6 h of exposure to [<sup>212</sup>Pb]Pb-DOTAMTATE drug product vials, showing no remaining colonies as compared to the vials containing only media and drug formulation with no radiolabeled material, utilizing a low absorbed dose of no greater than 1.01 kGy. A sterility assessment of the two [<sup>212</sup>Pb]Pb-DOTAMTATE drug product vials containing the lowest total CFUs per vial displayed no microbial growth upon incubation for 14 d. <b><i>Conclusions:</i></b> This study suggests that <sup>212</sup>Pb in radiopharmaceuticals is a potent microbial cytotoxic agent with self-sterilizing properties.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2024.0208","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The cytotoxic effect of 212Pb on microbial growth was examined, using six microorganisms, at clinically relevant time points, to determine the potency of 212Pb as a self-sterilizing agent in radiopharmaceuticals using [212Pb]Pb-DOTAMTATE. Materials and Methods: Vials of radiolabeled [212Pb]Pb-DOTAMTATE, nonradiolabeled DOTAMTATE, and appropriate media were inoculated with Bacillus spizizenii, Candida albicans, Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus, or Aspergillus brasiliensis. Samples from each vial type were plated onto tryptic soy agar or Sabouraud dextrose plates and allowed to grow at optimal temperature for each strain to obtain quantifiable colony forming units (CFU). Results: Each microbial organism observed at least a 6 log reduction in total CFUs after 6 h of exposure to [212Pb]Pb-DOTAMTATE drug product vials, showing no remaining colonies as compared to the vials containing only media and drug formulation with no radiolabeled material, utilizing a low absorbed dose of no greater than 1.01 kGy. A sterility assessment of the two [212Pb]Pb-DOTAMTATE drug product vials containing the lowest total CFUs per vial displayed no microbial growth upon incubation for 14 d. Conclusions: This study suggests that 212Pb in radiopharmaceuticals is a potent microbial cytotoxic agent with self-sterilizing properties.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.80
自引率
2.90%
发文量
87
审稿时长
3 months
期刊介绍: Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信